Clinical relevance of VPAC1 receptor expression in early arthritis: Association with IL-6 and disease activity

PLoS ONE

Volumn 11, Issue 2, 2016, Pages

  Seoane, Iria V ^a   Ortiz, Ana M ^b   Piris, Lorena ^c   Lamana, Amalia ^b   Juarranz, Yasmina ^a   García Vicuña, Rosario ^b   González Álvaro, Isidoro ^b   Gomariz, Rosa P ^a   Martínez, Carmen ^a  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^b Instituto de Investigación Sanitaria del Hospital Universitario de La Princesa   (Spain)

^c HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMALARIAL AGENT; CORTICOSTEROID; DISEASE MODIFYING ANTIRHEUMATIC DRUG; INTERLEUKIN 6; LEFLUNOMIDE; MESSENGER RNA; METHOTREXATE; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR INHIBITOR; VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTOR 1; VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTOR 2; IL6 PROTEIN, HUMAN; VASOACTIVE INTESTINAL POLYPEPTIDE;

ADULT; AGED; ARTHRITIS; ARTICLE; BLOOD ANALYSIS; BLOOD SAMPLING; CONTROLLED STUDY; CORRELATION ANALYSIS; DAS28; DEMOGRAPHY; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; FOLLOW UP; HUMAN; HUMAN CELL; INFLAMMATION; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RHEUMATOID ARTHRITIS; SOCIAL STATUS; BLOOD; CASE CONTROL STUDY; GENE EXPRESSION REGULATION; METABOLISM; MONONUCLEAR CELL; PATHOPHYSIOLOGY; SEVERITY OF ILLNESS INDEX; SIGNAL TRANSDUCTION; SOCIAL CLASS; TIME FACTOR;

ADULT; AGED; ARTHRITIS, RHEUMATOID; CASE-CONTROL STUDIES; FEMALE; GENE EXPRESSION REGULATION; HUMANS; INTERLEUKIN-6; LEUKOCYTES, MONONUCLEAR; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; RECEPTORS, VASOACTIVE INTESTINAL PEPTIDE, TYPE II; RECEPTORS, VASOACTIVE INTESTINAL POLYPEPTIDE, TYPE I; SEVERITY OF ILLNESS INDEX; SIGNAL TRANSDUCTION; SOCIAL CLASS; TIME FACTORS; VASOACTIVE INTESTINAL PEPTIDE;

EID: 84973104036     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0149141     Document Type: Article

References (41)

1. Choy E, Taylor P, McAuliffe S, Roberts K, Sargeant I. Variation in the use of biologics in the management of rheumatoid arthritis across the UK. Curr Med Res Opin. 2012; 28:1733-1741. doi: 10.1185/03007995.2012.731388 PMID: 22978773
2. van Leeuwen MA, van Rijswijk MH, van der Heijde DM, Te Meerman GJ, van Riel PL, Houtman PM, et al. The acute-phase response in relation to radiographic progression in early rheumatoid arthritis: a prospective study during the first three years of the disease. Br J Rheumatol. 1993; 32 (Suppl 3):9-13. PMID: 8508266
3. Felson DT, Smolen JS, Wells G, Zhang B, van Tuyl LH, Funovits J, et al. American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Arthritis Rheum. 2011; 63:573-586. doi: 10.1002/art.30129 PMID: 21294106
4. Combe B, Landewe R, Lukas C, Bolosiu HD, Breedveld F, Dougados M, et al. EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis. 2007; 66:34-45. PMID: 16396980
5. Smolen JS, Aletaha D, Bijlsma JW, Breedveld FC, Boumpas D, Burmester G, et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis. 2010; 69:631-637. doi: 10.1136/ard.2009.123919 PMID: 20215140
6. Keystone EC, Smolen J, van Riel P. Developing an effective treatment algorithm for rheumatoid arthritis. Rheumatology (Oxford). 2012; 51 (Suppl 5):v48-54.
7. Gomariz RP, Martinez C, Abad C, Leceta J, Delgado M. Immunology of VIP: a review and therapeutical perspectives. Curr Pharm Des. 2001; 7:89-111. PMID: 11172702
8. Gonzalez-Rey E, Anderson P, Delgado M. Emerging roles of vasoactive intestinal peptide: a new approach for autoimmune therapy. Ann Rheum Dis. 2007; 66 (Suppl 3):iii70-76. PMID: 17934101
9. Delgado M, Ganea D. Anti-inflammatory neuropeptides: a new class of endogenous immunoregulatory agents. Brain Behav Immun. 2008; 22:1146-1151. doi: 10.1016/j.bbi.2008.06.001 PMID: 18598752
10. Juarranz MG, Santiago B, Torroba M, Gutierrez-Canas I, Palao G, Galindo M, et al. Vasoactive intestinal peptide modulates proinflammatory mediator synthesis in osteoarthritic and rheumatoid synovial cells. Rheumatology (Oxford). 2004; 43:416-422.
11. Gutierrez-Canas I, Juarranz Y, Santiago B, Martinez C, Gomariz RP, Pablos JL, et al. Immunoregulatory properties of vasoactive intestinal peptide in human T cell subsets: implications for rheumatoid arthritis. Brain Behav Immun. 2008; 22:312-317. PMID: 17951026
12. Martinez C, Ortiz AM, Juarranz Y, Lamana A, Seoane IV, Leceta J, et al. Serum levels of vasoactive intestinal peptide as a prognostic marker in early arthritis. PLoS One. 2014; 9:e85248. doi: 10.1371/journal.pone.0085248 PMID: 24409325
13. Jimeno R, Gomariz RP, Garin M, Gutierrez-Canas I, Gonzalez-Alvaro I, Carrion M, et al. The pathogenic Th profile of human activated memory Th cells in early rheumatoid arthritis can be modulated by VIP. J Mol Med (Berl). 2015; 93:457-467.
14. Juarranz Y, Abad C, Martinez C, Arranz A, Gutierrez-Canas I, Rosignoli F, et al. Protective effect of vasoactive intestinal peptide on bone destruction in the collagen-induced arthritis model of rheumatoid arthritis. Arthritis Res Ther. 2005; 7:R1034-1045. PMID: 16207319
15. Ganea D, Hooper KM, Kong W. The neuropeptide vasoactive intestinal peptide: direct effects on immune cells and involvement in inflammatory and autoimmune diseases. Acta Physiol (Oxf). 2015; 213:442-452.
16. Couvineau A, Laburthe M: VPAC receptors. structure, molecular pharmacology and interaction with accessory proteins. Br J Pharmacol. 2012; 166:42-50. doi: 10.1111/j.1476-5381.2011.01676.x PMID: 21951273
17. Lara-Marquez M, O'Dorisio M, O'Dorisio T, Shah M, Karacay B. Selective gene expression and activation-dependent regulation of vasoactive intestinal peptide receptor type 1 and type 2 in human T cells. J Immunol. 2001; 166:2522-2530. PMID: 11160313
18. Dorsam GP, Benton K, Failing J, Batra S. Vasoactive intestinal peptide signaling axis in human leukemia. World J Biol Chem. 2011; 2:146-160. doi: 10.4331/wjbc.v2.i6.146 PMID: 21765981
19. Hauk V, Fraccaroli L, Grasso E, Eimon A, Ramhorst R, Hubscher O, et al. Monocytes from Sjogren's syndrome patients display increased vasoactive intestinal peptide receptor 2 expression and impaired apoptotic cell phagocytosis. Clin Exp Immunol. 2014; 177:662-670. doi: 10.1111/cei.12378 PMID: 24827637
20. Sun W, Hong J, Zang YC, Liu X, Zhang JZ. Altered expression of vasoactive intestinal peptide receptors in T lymphocytes and aberrant Th1 immunity in multiple sclerosis. Int Immunol. 2006; 18:1691-1700. PMID: 17077178
21. Delgado M, Robledo G, Rueda B, Varela N, O'Valle F, Hernandez-Cortes P, et al. Genetic association of vasoactive intestinal peptide receptor with rheumatoid arthritis: altered expression and signal in immune cells. Arthritis Rheum. 2008; 58:1010-1019. doi: 10.1002/art.23482 PMID: 18383379
22. Juarranz Y, Gutierrez-Canas I, Santiago B, Carrion M, Pablos JL, Gomariz RP. Differential expression of vasoactive intestinal peptide and its functional receptors in human osteoarthritic and rheumatoid synovial fibroblasts. Arthritis Rheum. 2008; 58:1086-1095. doi: 10.1002/art.23403 PMID: 18383383
23. Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 1995; 38:44-48. PMID: 7818570
24. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3rd, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010; 62:2569-2581. doi: 10.1002/art.27584 PMID: 20872595
25. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988, 31:315-324. PMID: 3358796
26. Nishimoto N, Kishimoto T: Interleukin 6: from bench to bedside. Nat Clin Pract Rheumatol. 2006; 2:619-626. PMID: 17075601
27. Gonzalez-Alvaro I, Ortiz AM, Seoane IV, Garcia-Vicuna R, Martinez C, Gomariz RP. Biomarkers predicting a need for intensive treatment in patients with early arthritis. Curr Pharm Des. 2015; 21:170-181. PMID: 25163741
28. Kirwan JR, Hewlett SE, Heiberg T, Hughes RA, Carr M, Hehir M, et al. Incorporating the patient perspective into outcome assessment in rheumatoid arthritis-progress at OMERACT 7. J Rheumatol. 2005; 32:2250-2256. PMID: 16265712
29. Castrejon I, Ortiz AM, Garcia-Vicuna R, Lopez-Bote JP, Humbria A, Carmona L, et al. Are the C-reactive protein values and erythrocyte sedimentation rate equivalent when estimating the 28-joint disease activity score in rheumatoid arthritis? Clin Exp Rheumatol. 2008; 26:769-775. PMID: 19032807
30. Centola M, Cavet G, Shen Y, Ramanujan S, Knowlton N, Swan KA, et al. Development of a multi-biomarker disease activity test for rheumatoid arthritis. PLoS One. 2013; 8:e60635. doi: 10.1371/journal. pone.0060635 PMID: 23585841
31. Carrion M, Juarranz Y, Perez-Garcia S, Jimeno R, Pablos JL, Gomariz RP, et al. RNA sensors in human osteoarthritis and rheumatoid arthritis synovial fibroblasts: immune regulation by vasoactive intestinal peptide. Arthritis Rheum. 2011; 63:1626-1636. doi: 10.1002/art.30294 PMID: 21337319
32. Goetzl EJ, Voice JK, Shen S, Dorsam G, Kong Y, West KM, et al. Enhanced delayed-type hypersensitivity and diminished immediate-type hypersensitivity in mice lacking the inducible VPAC(2) receptor for vasoactive intestinal peptide. Proc Natl Acad Sci U S A. 2001; 98:13854-13859. PMID: 11698667
33. Tan YV, Abad C, Wang Y, Lopez R, Waschek JA. VPAC2 (vasoactive intestinal peptide receptor type 2) receptor deficient mice develop exacerbated experimental autoimmune encephalomyelitis with increased Th1/Th17 and reduced Th2/Treg responses. Brain Behav Immun. 2015; 44:167-175. doi: 10.1016/j.bbi.2014.09.020 PMID: 25305591
34. Voice JK, Grinninger C, Kong Y, Bangale Y, Paul S, Goetzl EJ. Roles of vasoactive intestinal peptide (VIP) in the expression of different immune phenotypes by wild-type mice and T cell-targeted type II VIP receptor transgenic mice. J Immunol. 2003; 170:308-314. PMID: 12496414
35. Jimeno R, Leceta J, Garin M, Ortiz AM, Mellado M, Rodriguez-Frade JM, et al. Th17 polarization of memory Th cells in early arthritis: the vasoactive intestinal peptide effect. J Leukoc Biol. 2015; 98:257-269. doi: 10.1189/jlb.3A0714-327R PMID: 25957307
36. Shimamoto K, Ito T, Ozaki Y, Amuro H, Tanaka A, Nishizawa T, et al. Serum interleukin 6 before and after therapy with tocilizumab is a principal biomarker in patients with rheumatoid arthritis. J Rheumatol. 2013; 40:1074-1081. doi: 10.3899/jrheum.121389 PMID: 23637318
37. Delgado M, Abad C, Martinez C, Juarranz MG, Arranz A, Gomariz RP, et al. Vasoactive intestinal peptide in the immune system: potential therapeutic role in inflammatory and autoimmune diseases. J Mol Med (Berl). 2002; 80:16-24.
38. Zhao PW, Jiang WG, Wang L, Jiang ZY, Shan YX, Jiang YF. Plasma levels of IL-37 and correlation with TNF-alpha, IL-17A, and disease activity during DMARD treatment of rheumatoid arthritis. PLoS One 2014; 9:e95346. doi: 10.1371/journal.pone.0095346 PMID: 24788826
39. Eriksson C, Rantapaa-Dahlqvist S, Sundqvist KG. Changes in chemokines and their receptors in blood during treatment with the TNF inhibitor infliximab in patients with rheumatoid arthritis. Scand J Rheumatol. 2013; 42:260-265. doi: 10.3109/03009742.2012.754937 PMID: 23379516
40. Heiberg T, Kvien TK, Mowinckel P, Aletaha D, Smolen JS, Hagen KB. Identification of disease activity and health status cut-off points for the symptom state acceptable to patients with rheumatoid arthritis. Ann Rheum Dis. 2008; 67:967-971. PMID: 17965118
41. Aletaha D, Funovits J, Ward MM, Smolen JS, Kvien TK. Perception of improvement in patients with rheumatoid arthritis varies with disease activity levels at baseline. Arthritis Rheum. 2009; 61:313-320. doi: 10.1002/art.24282 PMID: 19248136